Hospital Equipment Electric Hydraulic Adjustable Surgical Operating Theater Table

Dimension: 2040*500*580-930mm                    
Dimension of sections: Head rest: 280*325mm; Back section: 500*480mm; Kidney bridge:100*480mm; Seat section:530*480mm; Leg section: 510*236mm; 
Max. reversed trendelenburg:  ≥20°                    
Max. trendelenburg:  ≥15°                    
Max. lateral tilt:  ≥15°                    
Head rest raised from horizontal:  ≥45°                    
Head rest lowered from horizontal:  ≥90°                    
Back section raised from horizontal:  ≥85°                    
Back section lowered from horizontal:  ≥45°                    
Leg section lowered from horizontal:  ≥90°                    
Leg section opened:  ≥90°    
Tabletop rotation horizontal: ≥180°    
Backward and forward movement: ≥400mm                                    
Lifting speed: 4-16mm/s                    
Safe working load: 250kg    
About our company
Sinsur Industry Co., Limited, is a professional supplier of medical equipments, specialized in medical beds, operating table, shadowless lamp in operating room, and medical trolleys, etc since the year 2010 with a high international commercial reputation. We have exported to many countries and now we are very familiar with these countries commoercial habits. 

We have our own factory located in Jining, Shandong with our own professional and efficient R&D team which guarantees all your requirements realized and make OEM products according to your ideas. Our workers are well trained and professional in producing medical instruments. Our sales team, is not only professional in international trade, but they are also experts in medical beds, operating table, shadowless lamp, etc. We are sure, we can give you a one-stop, full satisfaction trading experience. 

We have passed ISO, CE and FDA certifications and we always adhere to "we care, you are at ease" principle. Contact us now and let's do something perfect.



 

Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
It was reviewed and approved under the Food and Drug Administration`s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor positive advanced breast cancer.
We produce a series of complete intermediates for Palbociclib, intermediate I (CAS No. 571188-59-5), intermediate II (CAS No. 1013916-37-4) and intermediate III (CAS No. 1016636-76-2) etc.

All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.

Palbociclib Intermediates

Palbociclib Intermediates,Cas 571188-59-5,Cas 1013916-37-4,Cas 1016636-76-2

Nanjing Sunshine Biotech Co., Ltd , http://www.sunshine-bio.com